Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)

The objectives of this study were to evaluate the safety profile of aflibercept and health-related quality of life (HRQL) in patients with metastatic colorectal cancer (mCRC) provided with aflibercept access before marketing authorization. Patients received aflibercept followed by FOLFIRI (fluoroura...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical colorectal cancer 2019-09, Vol.18 (3), p.183-191.e3
Hauptverfasser:	Riechelmann, Rachel P., Srimuninnimit, Vichien, Bordonaro, Roberto, Kavan, Petr, Di Bartolomeo, Maria, Maiello, Evaristo, Cicin, Irfan, García-Alfonso, Pilar, Chau, Ian, Fedyanin, Mikhail Y., Martos, Carlos Fernández, Ter-Ovanesov, Mikhail, Peeters, Marc, Ko, Yoo-Joung, Yalcin, Suayib, Karthaus, Meinolf, Aparicio, Jorge, Heinemann, Volker, Picard, Pascaline, Bury, Denise, Drea, Edward, Sobrero, Alberto
Format:	Artikel
Sprache:	eng
Schlagworte:	Antiangiogenic Colorectal neoplasms Patient-reported outcome measures Receptors Vascular endothelial growth factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!